Tags

Type your tag names separated by a space and hit enter

Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in women of childbearing age: risks versus benefits.
Expert Rev Clin Pharmacol 2015; 8(2):221-31ER

Abstract

Angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) are effective and widely used antihypertensive drugs. Exposure to these agents is known to be harmful to the fetus in the second and third trimesters of pregnancy. Concerns have also been raised about the risk of congenital malformations if ACEIs or ARBs are taken during the first trimester of pregnancy. The evidence to date, however, is conflicting and observed malformations may be due to confounders such as undiagnosed diabetes or maternal obesity, other antihypertensive medications or the hypertension itself. Nonetheless, in women who become pregnant while taking an ACEI or ARB, the drug should be stopped as soon as possible. In women with chronic kidney disease and proteinuria, it may be appropriate to continue taking an ACEI or ARB until the pregnancy is confirmed because of the significant benefit to their kidney function and the lower fertility rate in these patients.

Authors+Show Affiliations

University Hospitals Birmingham NHS Foundation Trust, Edgbaston, Birmingham, B15 2WB, UK.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

25612630

Citation

Pucci, Mark, et al. "Angiotensin-converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Women of Childbearing Age: Risks Versus Benefits." Expert Review of Clinical Pharmacology, vol. 8, no. 2, 2015, pp. 221-31.
Pucci M, Sarween N, Knox E, et al. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in women of childbearing age: risks versus benefits. Expert Rev Clin Pharmacol. 2015;8(2):221-31.
Pucci, M., Sarween, N., Knox, E., Lipkin, G., & Martin, U. (2015). Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in women of childbearing age: risks versus benefits. Expert Review of Clinical Pharmacology, 8(2), pp. 221-31. doi:10.1586/17512433.2015.1005074.
Pucci M, et al. Angiotensin-converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Women of Childbearing Age: Risks Versus Benefits. Expert Rev Clin Pharmacol. 2015;8(2):221-31. PubMed PMID: 25612630.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in women of childbearing age: risks versus benefits. AU - Pucci,Mark, AU - Sarween,Nadia, AU - Knox,Ellen, AU - Lipkin,Graham, AU - Martin,Una, Y1 - 2015/01/22/ PY - 2015/1/24/entrez PY - 2015/1/24/pubmed PY - 2015/9/29/medline KW - angiotensin receptor blockers KW - angiotensin-converting enzyme inhibitors KW - chronic kidney disease KW - congenital malformations KW - first trimester KW - hypertension KW - pregnancy KW - teratogenicity SP - 221 EP - 31 JF - Expert review of clinical pharmacology JO - Expert Rev Clin Pharmacol VL - 8 IS - 2 N2 - Angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) are effective and widely used antihypertensive drugs. Exposure to these agents is known to be harmful to the fetus in the second and third trimesters of pregnancy. Concerns have also been raised about the risk of congenital malformations if ACEIs or ARBs are taken during the first trimester of pregnancy. The evidence to date, however, is conflicting and observed malformations may be due to confounders such as undiagnosed diabetes or maternal obesity, other antihypertensive medications or the hypertension itself. Nonetheless, in women who become pregnant while taking an ACEI or ARB, the drug should be stopped as soon as possible. In women with chronic kidney disease and proteinuria, it may be appropriate to continue taking an ACEI or ARB until the pregnancy is confirmed because of the significant benefit to their kidney function and the lower fertility rate in these patients. SN - 1751-2441 UR - https://www.unboundmedicine.com/medline/citation/25612630/Angiotensin_converting_enzyme_inhibitors_and_angiotensin_receptor_blockers_in_women_of_childbearing_age:_risks_versus_benefits_ L2 - http://www.tandfonline.com/doi/full/10.1586/17512433.2015.1005074 DB - PRIME DP - Unbound Medicine ER -